We are a Specialty Pharmaceutical Company with a Focus in Pain and Addiction

BEMA® Technology

A small, dissolvable polymer film for application to mucosal membranes (inner lining of cheek) which allows for transmucosal delivery of drugs.

 

Webcast: Clonidine Topical Gel Phase 3 Study Preliminary Results

Monday, March 30, at 8:00 a.m. ET (5:00 a.m. Pacific Time)

 

 CLICK HERE FOR CLONIDINE SLIDES

 

Webcast:   http://edge.media-server.com/m/p/j77ikhvk

____________________________

BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Year-end 2014 Financial Results

Monday, March 16, 2015 @ 5pm Eastern/2:00pm Pacific

Replay of call:

                       Domestic:            877-870-5176

                       International:   858-384-5517    

                       Conference ID:  1385073

  
____________________________________

 Dr. Mark A. Sirgo, President & ceo

to present at

the 27th annual roth Conference

monday, march 9, 2015 at 9:00 a.m. pT (12:00 p.m. edt)

click here for the webcast

___________________________________________

RBC Capital Markets Healthcare Conference

Tuesday, February 24, 2015 at 1:35 P.m. ET

click here for the audio webcast

______________________________________

BDSI INVESTOR & ANALYST UPDATE

FRIDAY, SEPTEMBER 5, 2014

12:00 TO 2:00 P.M. ET

 

CLICK HERE FOR THE REPLAY OF WEBCAST 

 

Get the latest details on our products and services.

Top News

BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development
Previously announced interim data showed pain improvement compared to placebo; results not replicated in patients enrolled post interim analysis


BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Year-End 2014 Financial Results
2014 - A Year of Many Significant Milestones, with More Expected for 2015, as BDSI Continues its Growth as an Integrated Specialty Pharmaceutical Company